• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).

作者信息

Zhang Yue, Qu Shiqiang, Wang Qianfei, Li Jianyong, Xu Zefeng, Qin Tiejun, Huang Gang, Xiao Zhijian

机构信息

a MDS and MPN Centre , Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Tianjin , China.

b State Key Laboratory of Experimental Hematology , Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Tianjin , China.

出版信息

Leuk Lymphoma. 2018 Oct;59(10):2506-2508. doi: 10.1080/10428194.2018.1427855. Epub 2018 Jan 31.

DOI:10.1080/10428194.2018.1427855
PMID:29384404
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9204506/
Abstract
摘要

相似文献

1
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).一名患有t(5;9)(q32;q34)的慢性嗜酸性粒细胞白血病患者中，血小板衍生生长因子受体B（PDGFRB）与mTOR信号通路的内在抑制因子结节性硬化症复合物1（TSC1）发生了一种新型融合。
Leuk Lymphoma. 2018 Oct;59(10):2506-2508. doi: 10.1080/10428194.2018.1427855. Epub 2018 Jan 31.
2
A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).一名患有慢性骨髓增殖性肿瘤且有8号和5号染色体插入（ins(8;5)）的患者中发现一种新型PCM1-PDGFRB融合基因。
Acta Haematol. 2017;138(4):198-200. doi: 10.1159/000484077. Epub 2017 Nov 24.
3
A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).一名患有t(2;5)(q37;q31)的慢性嗜酸性粒细胞白血病患者中涉及PDGFRB和GCC2的一种新型融合基因。
Mol Genet Genomic Med. 2019 Apr;7(4):e00591. doi: 10.1002/mgg3.591. Epub 2019 Jan 29.
4
Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.在一例嗜酸性粒细胞增多性髓系肿瘤中发现伴有NUMA1-PDGFRB融合的新型t(5;11)(q32;q13.4)，该患者对甲磺酸伊马替尼有反应。
Cancer Genet. 2017 Apr;212-213:38-44. doi: 10.1016/j.cancergen.2017.03.004. Epub 2017 Mar 27.
5
Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.携带ETV6-PDGFRA融合基因的伊马替尼无反应性慢性嗜酸性粒细胞白血病
Leuk Lymphoma. 2015 Mar;56(3):768-9. doi: 10.3109/10428194.2014.938330. Epub 2014 Aug 18.
6
Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.携带 TPM3-PDGFRB 融合的小儿慢性嗜酸性白血病患者的分子诊断和靶向治疗。
Pediatr Blood Cancer. 2011 Mar;56(3):463-6. doi: 10.1002/pbc.22800.
7
Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome.与嗜酸性粒细胞增多综合征中血小板衍生生长因子受体β（PDGFRB）重排相关的新型5号染色体倒位
JAMA Dermatol. 2016 Dec 1;152(12):1391-1393. doi: 10.1001/jamadermatol.2016.3175.
8
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.鉴定和功能表征嗜酸粒细胞相关髓系/淋巴肿瘤中的伊马替尼敏感的 DTD1-PDGFRB 和 CCDC88C-PDGFRB 融合基因。
Genes Chromosomes Cancer. 2014 May;53(5):411-21. doi: 10.1002/gcc.22153.
9
Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.一名血小板衍生生长因子受体β相关急性髓系白血病患者对甲磺酸伊马替尼有显著反应。
Int J Hematol. 2017 May;105(5):697-701. doi: 10.1007/s12185-016-2167-z. Epub 2016 Dec 20.
10
KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.KANK1是一种候选抑癌基因，在一种对伊马替尼敏感的伴有严重血小板增多症的髓系肿瘤中与PDGFRB融合。
Leukemia. 2010 May;24(5):1052-5. doi: 10.1038/leu.2010.13. Epub 2010 Feb 18.

引用本文的文献

1
[Guideline of the diagnosis and treatment of eosinophilic disorders (2024)].[嗜酸性粒细胞相关疾病的诊断和治疗指南（2024年）]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):1-7. doi: 10.3760/cma.j.cn121090-20231222-00334.
2
[ST13-PDGFRβ positive acute myeloid leukaemia: a case report and literature review].[ST13-PDGFRβ阳性急性髓系白血病：一例报告及文献综述]
Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):676-679. doi: 10.3760/cma.j.issn.0253-2727.2023.08.011.
3
Comprehensive Investigation of miRNome Identifies Novel Candidate miRNA-mRNA Interactions Implicated in T-Cell Acute Lymphoblastic Leukemia.miRNome 综合分析鉴定 T 细胞急性淋巴细胞白血病中涉及的新型候选 miRNA-mRNA 相互作用。
Neoplasia. 2019 Mar;21(3):294-310. doi: 10.1016/j.neo.2019.01.004. Epub 2019 Feb 11.
4
A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).一名患有t(2;5)(q37;q31)的慢性嗜酸性粒细胞白血病患者中涉及PDGFRB和GCC2的一种新型融合基因。
Mol Genet Genomic Med. 2019 Apr;7(4):e00591. doi: 10.1002/mgg3.591. Epub 2019 Jan 29.

本文引用的文献

1
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.伊马替尼用于慢性期或急变期伴有嗜酸性粒细胞增多及血小板衍生生长因子受体β（PDGFRB）重排的髓系/淋系肿瘤。
Ann Hematol. 2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19.
2
m-TOR inhibitors and their potential role in haematological malignancies.雷帕霉素靶蛋白抑制剂及其在血液系统恶性肿瘤中的潜在作用。
Br J Haematol. 2017 Jun;177(5):684-702. doi: 10.1111/bjh.14529. Epub 2017 Feb 1.
3
Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches.结节性硬化症复合体：从分子生物学到新型治疗方法
IUBMB Life. 2016 Dec;68(12):955-962. doi: 10.1002/iub.1579. Epub 2016 Oct 31.
4
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
5
Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells.雷帕霉素耐药且托瑞米芬敏感的mTOR信号传导促进白血病细胞的存活和增殖。
BMB Rep. 2016 Jan;49(1):63-8. doi: 10.5483/BMBRep.2016.49.1.201.
6
Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.三名嗜酸性粒细胞增多相关骨髓增殖性肿瘤患者中PDGFRB与MPRIP、CPSF6和GOLGB1的融合
Genes Chromosomes Cancer. 2015 Dec;54(12):762-70. doi: 10.1002/gcc.22287. Epub 2015 Sep 10.
7
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.mTOR的活性位点抑制剂靶向mTORC1和mTORC2的雷帕霉素抗性输出。
PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.
8
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.结节性硬化症复合物1-2（TSC1-TSC2）：控制细胞生长的分子总控开关
Biochem J. 2008 Jun 1;412(2):179-90. doi: 10.1042/BJ20080281.
9
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.雷帕霉素通过一种依赖胰岛素样生长因子-1受体（IGF-1R）的机制诱导Akt信号通路的反馈激活。
Oncogene. 2007 Mar 22;26(13):1932-40. doi: 10.1038/sj.onc.1209990. Epub 2006 Sep 25.
10
Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.错构瘤蛋白与结节性硬化蛋白（TSC1和TSC2基因产物）之间的相互作用。
Hum Mol Genet. 1998 Jun;7(6):1053-7. doi: 10.1093/hmg/7.6.1053.